Proficio Capital Partners LLC Takes Position in Certara, Inc. (NASDAQ:CERT)

Proficio Capital Partners LLC acquired a new stake in shares of Certara, Inc. (NASDAQ:CERT) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 13,856 shares of the company’s stock, valued at approximately $148,000.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Venturi Wealth Management LLC raised its stake in Certara by 839.1% during the 4th quarter. Venturi Wealth Management LLC now owns 2,808 shares of the company’s stock valued at $30,000 after purchasing an additional 2,509 shares during the period. Blue Trust Inc. raised its stake in Certara by 20.9% during the 4th quarter. Blue Trust Inc. now owns 4,747 shares of the company’s stock valued at $56,000 after purchasing an additional 822 shares during the period. KBC Group NV raised its stake in Certara by 48.2% during the 3rd quarter. KBC Group NV now owns 4,873 shares of the company’s stock valued at $57,000 after purchasing an additional 1,584 shares during the period. GAMMA Investing LLC raised its stake in Certara by 442.2% during the 4th quarter. GAMMA Investing LLC now owns 8,421 shares of the company’s stock valued at $90,000 after purchasing an additional 6,868 shares during the period. Finally, Moloney Securities Asset Management LLC acquired a new stake in Certara during the 4th quarter valued at $128,000. Institutional investors and hedge funds own 73.96% of the company’s stock.

Certara Trading Up 1.0 %

Certara stock opened at $11.01 on Thursday. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86. The company has a market capitalization of $1.77 billion, a price-to-earnings ratio of -55.05, a PEG ratio of 9.29 and a beta of 1.60. Certara, Inc. has a one year low of $9.41 and a one year high of $19.29. The company’s fifty day moving average price is $12.59 and its two-hundred day moving average price is $11.57.

Analysts Set New Price Targets

Several analysts have issued reports on CERT shares. Stephens reissued an “overweight” rating and set a $17.00 target price on shares of Certara in a research note on Thursday, February 27th. TD Cowen started coverage on shares of Certara in a research note on Thursday, February 27th. They issued a “buy” rating and a $16.00 price target on the stock. William Blair reaffirmed a “market perform” rating on shares of Certara in a research note on Thursday, February 27th. Finally, Barclays upped their price target on shares of Certara from $12.00 to $13.00 and gave the stock an “equal weight” rating in a research note on Friday, February 28th. Four equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, Certara currently has a consensus rating of “Moderate Buy” and a consensus price target of $15.83.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.